Covered recipient · General Payments record
CHRISTINA L FESER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$42,036.94
202 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,377.00 | 12 |
| Consulting Fee | $5,160.00 | 2 |
| Food and Beverage | $4,779.28 | 161 |
| Travel and Lodging | $4,434.69 | 23 |
| Education | $285.97 | 4 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $32,094.03 | 51 |
| Incyte Corporation | $6,443.53 | 17 |
| ABBVIE INC. | $555.43 | 19 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $452.66 | 20 |
| Regeneron Healthcare Solutions, Inc. | $412.44 | 16 |
| Novartis Pharmaceuticals Corporation | $334.04 | 14 |
| EPI Health, LLC | $258.77 | 10 |
| Janssen Biotech, Inc. | $231.86 | 8 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $199.07 | 8 |
| GENZYME CORPORATION | $178.96 | 8 |
| LEO Pharma Inc. | $174.60 | 4 |
| Allergan, Inc. | $142.51 | 1 |
| SANOFI-AVENTIS U.S. LLC | $127.44 | 1 |
| PFIZER INC. | $81.23 | 7 |
| Amgen Inc. | $63.41 | 3 |
| Galderma Laboratories, L.P. | $60.89 | 4 |
| Almirall LLC | $51.92 | 3 |
| Journey Medical Corporation | $51.51 | 3 |
| Acrotech Biopharma LLC | $51.35 | 1 |
| Sandoz Inc. | $41.30 | 2 |
| Nabriva Therapeutics, plc | $29.99 | 2 |
Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHRISTINA L FESER
NPI 1902122096 · CMS profile ID 987138
Allopathic & Osteopathic Physicians / Dermatology
CLARKSVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- CHRISTINA L FESER, NPI 1902122096, CMS profile ID 987138, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–202 of 202 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902122096?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
202 matching records · $42,036.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–202 of 202.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $17.11 | 01/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949230541 | CMS |
| Sun Pharmaceutical Industries Inc. | $12.83 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947744769 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $370,050.68 | 135 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $832,527.04 | 312 |
| PY2023 | Principal investigator | $586,635.15 | 227 |
| PY2022 | Principal investigator | $689,960.22 | 160 |
| PY2021 | Principal investigator | $319,512.25 | 41 |
| PY2020 | Principal investigator | $305,615.76 | 31 |
| PY2019 | Recipient | $70,014.15 | 2 |
| PY2019 | Principal investigator | $217,116.57 | 46 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
135 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202535045 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 12/19/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240539898 |
| Principal investigator 1 | Incyte Corporation | $1,100.00 | 12/19/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540472 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 12/19/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540475 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539903 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539907 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539911 |
| Principal investigator 1 | Eli Lilly and Company | $16,661.00 | 11/25/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187881954 |
| Principal investigator 1 | Incyte Corporation | $2,550.00 | 11/19/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1240539893 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,000.00 | 11/19/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288517 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $800.00 | 11/19/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288525 |
| Principal investigator 1 | Incyte Corporation | $80.10 | 11/14/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539890 |
| Principal investigator 1 | ABBVIE INC. | $1,862.00 | 11/12/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202523903 |
| Principal investigator 1 | ABBVIE INC. | $583.87 | 11/06/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202523523 |
| Principal investigator 1 | ABBVIE INC. | $2,275.43 | 11/06/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202523525 |
| Principal investigator 1 | ABBVIE INC. | $497.80 | 11/04/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202521107 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity International Clinical Research | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235996563 |
| Principal investigator 1 | ABBVIE INC. | $2,396.18 | 10/15/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202517035 |
| Principal investigator 1 | ABBVIE INC. | $1,675.00 | 10/15/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202517037 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 10/15/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286975 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286977 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 10/15/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286979 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $216.78 | 10/08/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190307147 |
| Principal investigator 1 | Eli Lilly and Company | $44,882.00 | 10/01/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HO | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187880061 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,624.15 | 09/19/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HOLDING LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223285746 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 09/17/2025 | Non-covered Recipient Entity EXIMIA RESEARCH ACQUISITION HOLDING LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223285606 |
| Principal investigator 1 | Incyte Corporation | $829.80 | 09/10/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539886 |
| Principal investigator 1 | ABBVIE INC. | $2,244.52 | 09/08/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202510216 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,370.50 | 08/01/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190307149 |
| Principal investigator 1 | ABBVIE INC. | $3,392.80 | 07/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202494673 |
| Principal investigator 1 | Incyte Corporation | $671.00 | 07/02/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470230 |
| Principal investigator 1 | Incyte Corporation | $1,518.00 | 06/20/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470222 |
| Principal investigator 1 | Incyte Corporation | $1,214.40 | 06/20/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470226 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,700.00 | 06/16/2025 | Non-covered Recipient Entity International Clinical Research Tennessee Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226119894 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 06/13/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470214 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 06/13/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470216 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 06/13/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470220 |
| Principal investigator 1 | Incyte Corporation | $1,236.60 | 06/11/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470224 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 06/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202490505 |
| Principal investigator 1 | Incyte Corporation | $1,538.00 | 05/14/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470192 |
| Principal investigator 1 | Incyte Corporation | $1,622.00 | 05/14/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470202 |
| Principal investigator 1 | Incyte Corporation | $2,770.00 | 05/14/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470208 |
| Principal investigator 1 | Incyte Corporation | $866.80 | 05/14/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470212 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 05/09/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470218 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,925.00 | 05/07/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223279128 |
| Principal investigator 1 | Incyte Corporation | $1,750.50 | 05/02/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470210 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539806 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539811 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539814 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539820 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539824 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539828 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539837 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539841 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539845 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539849 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539853 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539856 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539861 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539866 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539870 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 05/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539874 |
| Principal investigator 1 | Incyte Corporation | $1,058.25 | 04/24/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240539759 |
| Principal investigator 1 | Incyte Corporation | $3,570.20 | 04/18/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | No dispute reported | 06/30/2026 | 1240470196 |
| Principal investigator 1 | Incyte Corporation | $223.20 | 04/18/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | No dispute reported | 06/30/2026 | 1240470198 |
| Principal investigator 1 | Incyte Corporation | $1,533.60 | 04/11/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470194 |
| Principal investigator 1 | Incyte Corporation | $1,209.60 | 04/09/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470228 |
| Principal investigator 1 | Incyte Corporation | $3,658.80 | 04/08/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539747 |
| Principal investigator 1 | Incyte Corporation | $1,804.00 | 04/07/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240470200 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 04/07/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470204 |
| Principal investigator 1 | Incyte Corporation | $1,294.70 | 04/07/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240470206 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 04/04/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277602 |
| Principal investigator 1 | ABBVIE INC. | $3,494.20 | 04/03/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202472710 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539763 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539767 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539771 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539776 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539781 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539785 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539789 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539794 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539798 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539801 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539832 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539878 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 04/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539881 |
| Principal investigator 1 | Incyte Corporation | $550.00 | 04/01/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240539751 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,252.55 | 03/26/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277045 |
| Principal investigator 1 | Eli Lilly and Company | $1,162.80 | 03/25/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187883230 |
| Principal investigator 1 | Incyte Corporation | $1,384.20 | 03/19/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470176 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 03/11/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240539688 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $75.00 | 03/07/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223276123 |
| Principal investigator 1 | Incyte Corporation | $1,565.10 | 03/03/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470180 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240539739 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 03/03/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240539742 |
| Principal investigator 1 | Incyte Corporation | $1,538.00 | 02/21/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470168 |
| Principal investigator 1 | Incyte Corporation | $1,411.30 | 02/21/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470170 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,177.20 | 02/21/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275469 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 02/20/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202453190 |
| Principal investigator 1 | Incyte Corporation | $1,209.60 | 02/10/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470178 |
| Principal investigator 1 | Incyte Corporation | $1,311.20 | 02/05/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240470184 |
| Principal investigator 1 | Incyte Corporation | $1,639.00 | 02/05/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240470186 |
| Principal investigator 1 | Incyte Corporation | $4.25 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539694 |
| Principal investigator 1 | Incyte Corporation | $93.30 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539697 |
| Principal investigator 1 | Incyte Corporation | $155.50 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539723 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539727 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539731 |
| Principal investigator 1 | Incyte Corporation | $6.22 | 02/05/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240539735 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,923.35 | 02/05/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274837 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,555.00 | 02/03/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274653 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,044.83 | 01/29/2025 | Non-covered Recipient Entity International Clinical Research | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235996565 |
| Principal investigator 1 | Incyte Corporation | $87.00 | 01/24/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | No dispute reported | 06/30/2026 | 1240470172 |
| Principal investigator 1 | Incyte Corporation | $1,645.20 | 01/24/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470174 |
| Principal investigator 1 | Incyte Corporation | $7,981.42 | 01/23/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240539755 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 01/17/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540483 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 01/09/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540479 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/09/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240540488 |
| Principal investigator 1 | Eli Lilly and Company | $68,195.00 | 01/08/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | No dispute reported | 06/30/2026 | 1187882180 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 01/08/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470166 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 01/08/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470182 |
| Principal investigator 1 | Incyte Corporation | $1,146.60 | 01/08/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240470188 |
| Principal investigator 1 | Incyte Corporation | $105.00 | 01/08/2025 | Covered Recipient Teaching Hospital Beth Israel Deaconess Medical Center | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240470190 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,854.50 | 01/08/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273789 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 01/08/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223273791 |
| Principal investigator 1 | Eli Lilly and Company | $3,646.80 | 01/07/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187881988 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 01/03/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273525 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,008.50 | 01/03/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273527 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 01/03/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273529 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,050.00 | 01/03/2025 | Non-covered Recipient Entity INT CLIN RESEARCH TENNESSEE LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273531 |
| Principal investigator 1 | Incyte Corporation | $84.80 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539690 |
| Principal investigator 1 | Incyte Corporation | $339.20 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539701 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539705 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539709 |
| Principal investigator 1 | Incyte Corporation | $69.94 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539714 |
| Principal investigator 1 | Incyte Corporation | $106.00 | 01/02/2025 | Non-covered Recipient Entity INTERNATIONAL CLINICAL RESEARCH TENNESSEE LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240539718 |